Helix Biopharma Corp., of Toronto, announced in its financial results for the quarter ending Jan. 31, 2017, that its wholly owned subsidiary, Helix Immuno-Oncology signed a non-binding letter of intent with KEN Poland LLP for approximately $30 million in support of the proposed European Centre for Cancer Immunotherapy.